Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Merck & Co., Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.88, while Merck & Co., Inc. trades at $133.65 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while YieldMax AMD Option Income Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | MRK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $131.84 |
52-Week Low | $29.80 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.90, up 3.01% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, including $0.68 on August 5, 2026, but key valuation ratios like P/E and P/S are unavailable. Recent news highlights high yield potential but cautions on net asset value erosion amid AMD stock volatility.
Outlook hinges on AMD's performance; the ETF offers income via call spreads but faces NAV decline risks if AMD rallies sharply. Investors should weigh high distributions against potential capital depreciation, with sentiment mixed among analysts citing sustainability concerns.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
